NESS ZIONA, Israel — September 4, 2025 — Leads & Copy — BiomX Inc. (NYSE American: PHGE) announced that CEO Jonathan Solomon will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, September 7-9, 2025.
The presentation, titled “Phage Therapy: A Novel Approach to Chronic Diabetic Foot Infections,” will be held on September 8th from 4:30 – 5:00 PM ET and will focus on positive topline results from the Company’s Phase 2 trial evaluating BX211 for the treatment of DFO.
BX211 is a phage treatment for diabetic foot infections (DFO) associated with S. aureus. In March 2025, BiomX announced positive topline results from the Phase 2 trial in which BX211 was demonstrated to be safe and well-tolerated.
BiomX is currently planning a registrational trial, pending discussions and feedback from the Food and Drug Administration (FDA).
Investors attending the event may request a one-on-one meeting with BiomX through their H.C. Wainwright representative or e-mail meetings@hcwco.com.
Ben Cohen, Head Corporate Communications, benc@biomx.com
Source: BiomX
